Table 6: T.SPOT.TB indeterminate versus T.SPOT.TB determinate results. Univariate analyses.

Clinical and laboratory findingsIndeterminate T.SPOT.TB ( )Determinate T.SPOT.TB ( ) value

Age, years, mean ± SD 0.079
Patients with risk factors for LTBI, (%)1 (25)8 (9)0.34
SLE disease duration, median (IQR)318 (117–351)138 (60–207)0.028
SLEDAI, mean ± SD 0.42
SLICC, median (IQR)1 (1–1.75)0 (0-1)0.002
dsDNAn, UI/mL, median 13.5 (6.77–332.75)14.50 (3.72–43.50)0.85
Prednisone > 7.5 mg/d, (%)0 (0)18 (33.3)0.31
Immunosuppressed patients, (%)3 (75)56 (63.6)0.64
Hydroxychloroquine treatment, (%)2 (50)77 (87.5)0.94
Steroid dosage, mg, mean ± SD 0.59
Steroid cumulative dose, mg, mean ± SD 0.09
Steroid cumulative dose/disease duration, mg/year, mean ± SD 0.82
Mycophenolate dose, mg, mean ± SD0 0.001
Mycophenolate cumulative dose, mg, mean ± SD0 0.001
Mycophenolate cumulative dose/disease duration, mg/year, mean ± SD0 0.001
Methotrexate dose, mg, mean ± SD 0.98
Methotrexate cumulative dose, mg, mean ± SD 0.66
Cumulative methotrexate dose/disease duration, mg/year, mean ± SD 0.60